JNJ-70218902
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control.
Product Specifications
UNSPSC
12352203
Target
CD3; Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[JNJ-70218902]
References & Citations
[1]Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022) : LB087-LB087. |[2]Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2x CD3 bispecific antibody, in cynomolgus monkey. (2022) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680043-500 1x 500 µL
P21 / WAF1 (WA-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680965-100 1x 100 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880050-100 1x 100 µL
IgA Secretory Component (SC05), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details